GMAB Stock Forecast & Price Target

Genmab's financial outlook is positively influenced by the impressive performance of its leading product, DARZALEX, which achieved worldwide net sales of $3.9 billion in 4Q25, surpassing prior estimates. The company anticipates a significant increase in royalties from DARZALEX, projecting approximately $722 million for 4Q25, bolstered by the product's strong growth trajectory and solid positioning in the multiple myeloma treatment arena. Furthermore, Genmab's robust pipeline of candidates across oncologic indications provides potential for numerous near- to medium-term clinical data catalysts, reinforcing its resilience in the competitive biotech sector.

Genmab faces a series of significant risks that contribute to a negative outlook for its stock, most notably the slowing sales of its leading product, Darzalex, along with the potential failure to secure label extensions for this drug. The recent Phase 3 trial results for Epcoritamab (Epkinly) revealed it did not meet its primary endpoint, leading to a substantial reduction in the probability of its approval in both first-line and relapsed settings. Additionally, broader concerns about a lack of market penetration for other products, along with possible failures in the company’s clinical pipeline, introduce further financial uncertainty and long-term dilution risks for investors.